Drug intelligence / Profile preview

MET-034i

Development stage: Preclinical
Lead developer: Metsera
Modality: Peptides, Small Molecules
Administration: Subcutaneous (anticipated Based On Class And Developer Statements)[7]

Overview

MET-034i is an ultra-long acting synthetic peptide developed by Metsera for the treatment of obesity. It acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, designed to promote weight loss through modulation of metabolic pathways involved in energy balance and appetite regulation. The drug utilizes Metsera’s proprietary HALO lipidation platform to extend its half-life and enable infrequent dosing. As of mid-2025, it is in preclinical or early clinical development with plans for combination studies with other metabolic peptides[1][2][7].

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on MET-034i.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MET-034i.

Explore the full profile